ID29028A
(id)
|
1998-09-18 |
2001-07-26 |
Basf Ag |
Pirolopirimidina sebagai penghambat protein kinase
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
DE60037455T2
(de)
|
1999-09-17 |
2008-11-27 |
Abbott Gmbh & Co. Kg |
Kinaseinhibitoren als arzneimittel
|
US6998391B2
(en)
|
2002-02-07 |
2006-02-14 |
Supergen.Inc. |
Method for treating diseases associated with abnormal kinase activity
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
WO2005005429A1
(en)
|
2003-06-30 |
2005-01-20 |
Cellular Genomics, Inc. |
Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
AP2006003620A0
(en)
|
2003-10-15 |
2006-06-30 |
Osi Pharm Inc |
Imidazopyrazine tyroshine kinase inhibitors
|
MXPA06011423A
(es)
|
2004-04-02 |
2007-01-23 |
Osi Pharm Inc |
Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
|
ES2605792T3
(es)
|
2004-05-13 |
2017-03-16 |
Icos Corporation |
Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
|
MX2007005857A
(es)
|
2004-11-17 |
2007-10-10 |
Mikana Therapeutics Inc |
Inhibidores de cinasa.
|
CN103554042B
(zh)
|
2004-11-18 |
2016-08-10 |
Synta医药公司 |
调节hsp90活性的***化合物
|
HUE025671T2
(en)
|
2005-02-04 |
2016-04-28 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
ES2397706T3
(es)
|
2005-02-18 |
2013-03-08 |
The Hong Kong Polytechnic University |
Método para la hidrosililación asimétrica de cetonas
|
WO2007041358A2
(en)
|
2005-09-30 |
2007-04-12 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
DK1945631T3
(da)
|
2005-10-28 |
2012-10-22 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
|
BRPI0618552B8
(pt)
|
2005-11-16 |
2021-05-25 |
Cell Therapeutics Inc |
compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
|
DK1951724T3
(da)
|
2005-11-17 |
2011-08-15 |
Osi Pharmaceuticals Llc |
Sammensmeltede bicykliske mTOR-inhibitorer
|
ES2390135T3
(es)
|
2005-11-22 |
2012-11-06 |
Merck Sharp & Dohme Corp. |
Compuestos tricíclicos útiles como inhibidores de quinasas
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
PL2474545T3
(pl)
|
2005-12-13 |
2017-04-28 |
Incyte Holdings Corporation |
Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
|
EP1968579A1
(en)
|
2005-12-30 |
2008-09-17 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
EP1996193A2
(en)
|
2006-03-13 |
2008-12-03 |
OSI Pharmaceuticals, Inc. |
Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
|
NZ601278A
(en)
|
2006-09-22 |
2013-09-27 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
CN104030990B
(zh)
|
2007-03-12 |
2017-01-04 |
Ym生物科学澳大利亚私人有限公司 |
苯基氨基嘧啶化合物及其用途
|
UA98955C2
(ru)
|
2007-03-23 |
2012-07-10 |
Амген Инк. |
Гетероциклические соединения и их применение
|
CA3143428A1
(en)
|
2007-03-28 |
2008-10-09 |
Pharmacyclics Llc |
8-amino-3-substituted-imidazo[1,5-a]pyrazine and use thereof as inhibitors of bruton's tyrosine kinase
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
AU2008262291A1
(en)
|
2007-06-11 |
2008-12-18 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
HUE043732T2
(hu)
|
2007-06-13 |
2019-09-30 |
Incyte Holdings Corp |
Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
RU2010128239A
(ru)
|
2007-12-13 |
2012-01-20 |
Новартис АГ (CH) |
Комбинации терапевтических средств, предназначенных для лечения рака
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
AU2009223640B2
(en)
|
2008-03-11 |
2013-07-04 |
Incyte Holdings Corporation |
Azetidine and cyclobutane derivatives as jak inhibitors
|
KR20110025224A
(ko)
|
2008-06-27 |
2011-03-09 |
아빌라 테라퓨틱스, 인크. |
헤테로아릴 화합물 및 이의 용도
|
US9095592B2
(en)
|
2008-11-07 |
2015-08-04 |
The Research Foundation For The State University Of New York |
Bruton's tyrosine kinase as anti-cancer drug target
|
EP2373313A4
(en)
|
2008-11-26 |
2012-06-13 |
Miikana Therapeutics Inc |
SUBSTITUTED PYRAZOL COMPOUNDS
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8557983B2
(en)
|
2008-12-04 |
2013-10-15 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8586754B2
(en)
|
2008-12-05 |
2013-11-19 |
Abbvie Inc. |
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
US8563735B2
(en)
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
JOP20190231A1
(ar)
|
2009-01-15 |
2017-06-16 |
Incyte Corp |
طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
|
ES2593427T3
(es)
|
2009-01-19 |
2016-12-09 |
Abbvie Inc. |
Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
|
RU2535217C2
(ru)
|
2009-02-06 |
2014-12-10 |
Ниппон Синяку Ко., Лтд. |
Производные аминопиразина и лекарственные средства
|
WO2010099379A1
(en)
|
2009-02-27 |
2010-09-02 |
Ambit Biosciences Corporation |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
US8765754B2
(en)
|
2009-04-29 |
2014-07-01 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
CA2761954C
(en)
|
2009-05-22 |
2018-07-31 |
Incyte Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
US9034875B2
(en)
|
2009-05-26 |
2015-05-19 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
KR20170037683A
(ko)
|
2009-05-26 |
2017-04-04 |
애브비 아일랜드 언리미티드 컴퍼니 |
암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
|
WO2011025685A1
(en)
|
2009-08-24 |
2011-03-03 |
Merck Sharp & Dohme Corp. |
Jak inhibition blocks rna interference associated toxicities
|
PL2473510T3
(pl)
|
2009-09-03 |
2014-11-28 |
Bristol Myers Squibb Co |
Inhibitory JAK2 i ich zastosowanie do leczenia chorób mieloproliferacyjnych i nowotworu
|
CN102596960B
(zh)
|
2009-10-09 |
2016-01-20 |
因西特控股公司 |
3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
|
RU2560162C2
(ru)
|
2010-02-08 |
2015-08-20 |
Мерк Шарп и Доум Б.В. |
СОЕДИНЕНИЯ 8-МЕТИЛ-1-ФЕНИЛИМИДАЗО[1, 5-а]ПИРАЗИНА
|
UY33288A
(es)
|
2010-03-25 |
2011-10-31 |
Glaxosmithkline Llc |
Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
|
US8604032B2
(en)
|
2010-05-21 |
2013-12-10 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
LT2578585T
(lt)
|
2010-05-31 |
2016-10-10 |
Ono Pharmaceutical Co., Ltd. |
Purinono darinys kaip btk kinazės inhibitorius
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
US20120053189A1
(en)
|
2010-06-28 |
2012-03-01 |
Pharmacyclics, Inc. |
Btk inhibitors for the treatment of immune mediated conditions
|
WO2012021444A1
(en)
|
2010-08-10 |
2012-02-16 |
Avila Therapeutics, Inc. |
Besylate salt of a btk inhibitor
|
JPWO2012020786A1
(ja)
|
2010-08-11 |
2013-10-28 |
日本新薬株式会社 |
医薬組成物
|
WO2012020787A1
(ja)
|
2010-08-11 |
2012-02-16 |
日本新薬株式会社 |
悪性リンパ腫治療剤
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
WO2012030913A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
EP2611794A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
CA2811805A1
(en)
|
2010-10-29 |
2012-05-03 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
US20120128665A1
(en)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment based on hypoxic status
|
WO2012068487A1
(en)
|
2010-11-18 |
2012-05-24 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
RU2593231C2
(ru)
|
2010-11-23 |
2016-08-10 |
ЭббВи Айэленд Анлимитед Компани |
Способы лечения с использованием селективных ингибиторов bcl-2
|
CN107266435A
(zh)
|
2010-11-23 |
2017-10-20 |
Abbvie 公司 |
细胞凋亡诱导剂的盐和晶形
|
MX2013006261A
(es)
|
2010-12-03 |
2013-10-01 |
Ym Biosciences Australia Pty |
Tratamiento de condiciones mediadas por jak2.
|
CA2824197C
(en)
|
2011-01-10 |
2020-02-25 |
Michael Martin |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
WO2012141796A2
(en)
|
2011-02-24 |
2012-10-18 |
Synta Pharmaceuticals Corp. |
Prostate cancer therapy with hsp90 inhibitory compounds
|
US20140045908A1
(en)
|
2011-02-25 |
2014-02-13 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
CA2760174A1
(en)
|
2011-12-01 |
2013-06-01 |
Pharmascience Inc. |
Protein kinase inhibitors and uses thereof
|
ES2590144T3
(es)
|
2011-04-04 |
2016-11-18 |
Pharmascience Inc. |
Inhibidores de proteína quinasa
|
WO2012155063A1
(en)
|
2011-05-11 |
2012-11-15 |
Synta Pharmaceuticals Corp. |
Treating cancer with an hsp90 inhibitory compound
|
BR112013029508B1
(pt)
|
2011-05-17 |
2022-05-03 |
Principia Biopharma, Inc. |
Composto, composição farmacêutica, e, uso do referido composto
|
US20140228418A1
(en)
|
2011-05-23 |
2014-08-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
WO2012162372A1
(en)
|
2011-05-24 |
2012-11-29 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
|
US20140194388A1
(en)
|
2011-05-26 |
2014-07-10 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with chk inhibitors
|
AU2012275275A1
(en)
|
2011-06-28 |
2014-01-23 |
Pharmacyclics Llc |
Methods and compositions for inhibition of bone resorption
|
JP2014520808A
(ja)
|
2011-07-07 |
2014-08-25 |
シンタ ファーマシューティカルズ コーポレーション |
Hsp90阻害化合物を用いた癌の治療
|
WO2013010136A2
(en)
|
2011-07-13 |
2013-01-17 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
CA2841887A1
(en)
|
2011-07-19 |
2013-01-24 |
Merck Sharp & Dohme B.V. |
4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
|
EA034558B1
(ru)
|
2011-07-19 |
2020-02-20 |
Мерк Шарп и Доум Б.В. |
4-ИМИДАЗО[1,5-a]ПИРИДАЗИН-1-ИЛ-БЕНЗАМИДЫ В КАЧЕСТВЕ Btk-ИНГИБИТОРОВ
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
EP2744494A1
(en)
|
2011-08-19 |
2014-06-25 |
Synta Pharmaceuticals Corporation |
Combination cancer therapy of hsp90 inhibitor with antimetabolite
|
RU2014111823A
(ru)
|
2011-08-29 |
2015-10-10 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения и их применения
|
CA2851808C
(en)
|
2011-10-19 |
2021-04-13 |
Pharmacyclics, Inc. |
Use of inhibitors of bruton's tyrosine kinase (btk)
|
US8628752B2
(en)
|
2011-10-28 |
2014-01-14 |
Synta Pharmaceuticals Corp. |
Methods of identifying HSP90 inhibitors with less ocular toxicity
|
JP2014532712A
(ja)
|
2011-11-02 |
2014-12-08 |
シンタ ファーマシューティカルズ コーポレーション |
トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法
|
US20140286902A1
(en)
|
2011-11-02 |
2014-09-25 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
JP2014533299A
(ja)
|
2011-11-14 |
2014-12-11 |
シンタ ファーマシューティカルズ コーポレーション |
Braf阻害剤とhsp90阻害剤の組合せ療法
|
SI2786996T1
(sl)
|
2011-11-29 |
2017-02-28 |
Ono Pharmaceutical Co., Ltd. |
Hidroklorid s purinonskimi derivati
|
US20140212425A1
(en)
|
2011-12-05 |
2014-07-31 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20140079636A1
(en)
|
2012-04-16 |
2014-03-20 |
Dinesh U. Chimmanamada |
Targeted therapeutics
|
EP2849751A1
(en)
|
2012-05-10 |
2015-03-25 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
WO2013170182A1
(en)
|
2012-05-11 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with an hsp90 inhibitory compound
|
AU2013262914A1
(en)
|
2012-05-16 |
2014-11-06 |
Synta Pharmaceuticals Corp. |
Pre-selection of subjects for therapeutic treatment with an Hsp90 inhibitor based on hypoxic status
|
DK3176170T3
(en)
|
2012-06-13 |
2019-01-28 |
Incyte Holdings Corp |
SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
EP2885303B1
(en)
|
2012-08-17 |
2018-12-26 |
CoNCERT Pharmaceuticals, Inc. |
Deuterated baricitinib
|
KR20200110711A
(ko)
*
|
2012-09-07 |
2020-09-24 |
제넨테크, 인크. |
Ii형 항-cd20 항체와 선택적 bcl-2 억제제와의 병용 치료요법
|
US20140206681A1
(en)
|
2013-01-23 |
2014-07-24 |
Ronald M. Kim |
Btk inhibitors
|
US20160022683A1
(en)
|
2013-03-14 |
2016-01-28 |
Pharmacyclics Llc |
Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
|
WO2014143807A2
(en)
|
2013-03-15 |
2014-09-18 |
Stromatt Scott |
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
|
MX369503B
(es)
*
|
2013-04-08 |
2019-11-11 |
Pharmacyclics Llc |
Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
|
JP6204568B2
(ja)
|
2013-04-25 |
2017-09-27 |
ベイジーン,リミテッド |
タンパク質キナーゼ阻害剤としての縮合複素環化合物
|
KR20160013204A
(ko)
*
|
2013-05-30 |
2016-02-03 |
인피니티 파마슈티칼스, 인코포레이티드 |
Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
|
US20150005277A1
(en)
|
2013-06-28 |
2015-01-01 |
Beigene, Ltd. |
Protein Kinase Inhibitors and Uses Thereof
|
WO2015018522A1
(en)
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
|
KR20160066554A
(ko)
*
|
2013-10-25 |
2016-06-10 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
|
US10328080B2
(en)
|
2013-12-05 |
2019-06-25 |
Acerta Pharma, B.V. |
Therapeutic combination of PI3K inhibitor and a BTK inhibitor
|
TW201613644A
(en)
|
2014-06-17 |
2016-04-16 |
Acerta Pharma Bv |
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
|
EP3177366A4
(en)
|
2014-08-08 |
2018-04-04 |
Pharmacyclics LLC |
Bruton's tyrosine kinase inhibitor combinations and uses thereof
|
TW201618774A
(zh)
*
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
使用btk抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
|
AR101504A1
(es)
*
|
2014-08-11 |
2016-12-21 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
|
DK3179992T3
(da)
*
|
2014-08-11 |
2022-07-11 |
Acerta Pharma Bv |
Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
|
HRP20211813T1
(hr)
*
|
2014-08-11 |
2022-03-04 |
Acerta Pharma B.V. |
Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
|
US9717745B2
(en)
*
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
RU2018103913A
(ru)
*
|
2015-07-02 |
2019-08-02 |
Асерта Фарма Б.В. |
Твердые формы и композиции (s)-4-(8-амино-3-(1-(бут-2- иноил)пирролидин-2-ил)имидазо[1,5-a]пиразин-1-ил)-n-(пиридин-2-ил)бензамида
|
US20170071962A1
(en)
*
|
2015-09-11 |
2017-03-16 |
Acerta Pharma B.V. |
Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
|
AU2017326558B2
(en)
*
|
2016-09-19 |
2022-01-06 |
Mei Pharma, Inc. |
Combination therapy
|
US20190376971A1
(en)
*
|
2017-01-19 |
2019-12-12 |
Acerta Pharma B.V. |
Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
|